Luminex magnetic carboxylated microsphere beads, or equivalent
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), is seeking Luminex magnetic carboxylated microsphere beads, or equivalent, through a Combined Synopsis/Solicitation (RFQ). These beads are crucial for fluorescent magnetic immunoassays (FMIA) supporting viral research, including RSV and influenza, by enabling high-throughput evaluation of antigen-specific immune responses. Quotes are due June 16, 2026.
Scope of Work
The requirement is for magnetic carboxylated microsphere beads with specific physical, chemical, and functional properties:
- Product: Magnetic carboxylated microsphere beads.
- Properties: Must have carboxylated (COOH) functional groups, superparamagnetic or paramagnetic properties for magnetic separation, and be suitable for amine coupling chemistry (EDC/NHS or equivalent).
- Functionality: Must have distinct fluorescent signatures identifiable by flow cytometry, with a minimum of 20 distinct bead regions/sets for multiplex applications, and compatibility with multi-laser flow cytometry systems (minimum 2-laser).
- Quality & Stability: Minimum 6-month shelf life from delivery, lot-to-lot consistency in fluorescent intensity and magnetic properties, and free from microbial contamination, aggregation, or clumping.
- Delivery: Within 60 days of contract award to US FDA/CBER, Silver Spring, MD 20993.
Contract Details
- Contract Type: Firm Fixed-Price for commercial products.
- Solicitation Number: 75F40126Q134073.
- NAICS Code: 325413 – In-Vitro Diagnostic Substance Manufacturing (Small Business Size Standard: 1,250 employees).
- Set-Aside: This is a full and open solicitation; any sized business may submit a quote.
Submission & Evaluation
- Submission Deadline: Quotes must be submitted via email to Suzanne Martella (suzanne.martella@fda.hhs.gov) by June 16, 2026, 3:30 PM Central Time.
- Evaluation Criteria: Award will be made to the lowest priced technically acceptable (LPTA) responsible quoter. Technical acceptability will be determined by sufficient technical information demonstrating that quoted products meet or exceed all specified requirements.
- Pricing: Quoters must detail prices for the Schedule of Supplies/Services, including shipping, and are encouraged to submit a vendor quote. Prices must remain firm through September 30, 2026.
- Required Information: Include the firm's Unique Entity ID (UEI) number. Authorized resellers must provide a letter of supply. An Accessibility Conformance Report (ACR) or equivalent documentation is required for ICT accessibility standards (Section 508).
Additional Notes
The solicitation incorporates applicable FAR and HHSAR clauses by reference. Submitted documents must not contain macros.